Illumina

YTD

ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.

CEO

Jacob Thaysen

CEOJacob Thaysen

Employees

10,370

Employees10,370

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

10,370

Employees10,370

ILMN Key Statistics

Market cap

21.56B

Market cap21.56B

Price-Earnings ratio

32.44

Price-Earnings ratio32.44

Dividend yield

—

Dividend yield—

Average volume

2.14M

Average volume2.14M

High today

$143.95

High today$143.95

Low today

$139.79

Low today$139.79

Open price

$142.73

Open price$142.73

Volume

2.28M

Volume2.28M

52 Week high

$155.53

52 Week high$155.53

52 Week low

$68.70

52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $140.00, with a market capitalization of 21.56B. The stock trades at a price-to-earnings (P/E) ratio of 32.44.

On 2026-02-02, Illumina(ILMN) stock moved within a range of $139.79 to $143.95. With shares now at $140.00, the stock is trading +0.2% above its intraday low and -2.7% below the session's peak.

Trading activity shows a volume of 2.28M, compared to an average daily volume of 2.14M.

The stock's 52-week range extends from a low of $68.70 to a high of $155.53.

ILMN News

Simply Wall St 9h

Does CMS Backing of TruSight Oncology Recast Illumina’s Clinical Genomics Potential?

Illumina, Inc. recently secured CMS reimbursement for its FDA-approved TruSight Oncology Comprehensive in vitro diagnostic test, effective January 1, 2026, at a...

Simply Wall St 2d

A Look At Illumina Valuation As Recent Returns Contrast With Longer Term Declines

Advertisement Recent performance context for Illumina stock Illumina (ILMN) has drawn investor attention after a 1-month return of 7.8% and a past 3-month ret...

TipRanks 3d

Illumina Completes SomaLogic Acquisition, Expands Proteomics Capabilities

The latest announcement is out from Illumina ( (ILMN) ). On January 30, 2026, Illumina completed its previously announced acquisition of SomaLogic and related...

Analyst ratings

43%

of 23 ratings

Buy

39.1%

Hold

43.5%

Sell

17.4%

More ILMN News

TipRanks 3d

Standard BioTools completes sale of SomaLogic to Illumina

Standard BioTools (LAB) announced it has completed the previously announced sale of SomaLogic to Illumina (ILMN) for $350 million in upfront cash and up to $75...

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.